Abstract
Purpose
The clinical risk scores (CRSs) of Fong and Nordlinger are used to predict the outcome of patients with colorectal liver metastases (CRLMs). This study investigated whether CRSs could predict the overall survival of patients with CRLM treated with or without neoadjuvant chemotherapy prior to resection.
Methods
Patients with CRLM undergoing liver resection were analyzed retrospectively. The primary outcome measure was overall survival with vs. without neoadjuvant chemotherapy.
Results
Between August 2002 and October 2011, 300 patients underwent liver resection for CRLMs at a large university hospital in Germany. Group A comprised 117 patients who received neoadjuvant chemotherapy and group B comprised 71 patients who did not. The Fong score predicted overall survival for patients who did not receive chemotherapy (p = 0.02), but not for those treated with chemotherapy (p = 0.69). The Nordlinger score was not predictive for either of the groups (p = 0.71 vs. p = 0.08 for groups A and B, respectively). Subgroup analysis of the Nordlinger score identified better overall survival in the high-risk group treated with chemotherapy (p = 0.05). Multivariate analysis identified a resection margin of <1 cm [OR 0.622 (95 % CI: 0.17–2.31); p = 0.044], age >60 years [OR 0.535 (95 % CI: 0.16–1.77); p = 0.022] and number of metastases >4 [OR 0.189 (95 % CI: 0.06–0.61); p = 0.018] as independent prognostic factors for overall survival.
Conclusion
Thus, CRSs were not reliable prognostic tools for patients treated with neoadjuvant chemotherapy before liver resection in this analysis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion. 1969;2:179–86.
Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–9.
Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Ärztebl Int. 2010;107:335–42.
Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2009;1(27):3677–83.
Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20:985–92.
Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.
Amano R, Yamada N, Nakata B, Kimura K, Yoshiro M, Ohira M, Hirakawa K. A prognostic indicator for the resection of liver metastasis of colorectal cancer. Surg Today. 2014;44(7):1287–92.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18 (discussion 318–321).
Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;1(77):1254–62.
Belgihiti J, Clavien PA, Gadzijev E, Garden JO, Lau W, Makuuchi M. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333–9.
Folprecht G, Gruenberger T, Bechstein W, Raab H-R, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25(5):1018–25.
Hamady ZZR, Lodge JPA, Welsh FK, Toogood GJ, White A, John T, et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg. 2014;259:543–8.
Ayez N, Lalmahomed ZS, van der Pool AEM, Vergouwe Y, van Montfort K, de Jonge J, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18:2757–63.
Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:3279–88.
Merkel S, Bialecki D, Meyer T, Müller V, Papadopoulos T, Hohenberger W. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J Surg Oncol. 2009;1(100):349–57.
Maithel SK, Gönen M, Ito H, Dematteo RP, Allen PJ, Fong Y, et al. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery. 2012;151:162–70.
Conflict of interest
Teresa Schreckenbach and her co-authors have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. A. Schnitzbauer and F. Ulrich: co-senior authorship.
Rights and permissions
About this article
Cite this article
Schreckenbach, T., Malkomes, P., Bechstein, W.O. et al. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today 45, 1527–1534 (2015). https://doi.org/10.1007/s00595-014-1108-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-014-1108-9